Analysts Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Price Target at $11.67

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $11.6667.

Separately, Weiss Ratings cut Acrivon Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 29th.

Institutional Trading of Acrivon Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Focus Partners Wealth purchased a new position in shares of Acrivon Therapeutics during the 3rd quarter valued at $36,000. Schonfeld Strategic Advisors LLC bought a new stake in Acrivon Therapeutics during the fourth quarter valued at $40,000. Vermillion & White Wealth Management Group LLC purchased a new position in Acrivon Therapeutics during the fourth quarter worth about $44,000. Quadrature Capital Ltd purchased a new stake in shares of Acrivon Therapeutics in the 4th quarter valued at about $50,000. Finally, Invesco Ltd. bought a new stake in shares of Acrivon Therapeutics during the 1st quarter valued at about $72,000. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Price Performance

Shares of ACRV stock opened at $1.72 on Monday. The stock has a market capitalization of $73.62 million, a price-to-earnings ratio of -0.86 and a beta of 1.82. The company’s fifty day simple moving average is $1.70 and its two-hundred day simple moving average is $1.77. Acrivon Therapeutics has a 1 year low of $1.20 and a 1 year high of $3.56.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.49) EPS for the quarter, hitting analysts’ consensus estimates of ($0.49). Equities research analysts anticipate that Acrivon Therapeutics will post -1.92 EPS for the current year.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.